Cure My Disease

Don't miss your cure!

 Log in / Sign up

A sharper MRI could reveal radiation sensitivity of brain tumors

NCT ID NCT04700748

Diagnosis Sponsor: Lund University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers at Lund University Hospital are testing a new MRI technique called DIVIDE to see if it can measure how sensitive brain metastases are to radiation. Today, doctors only see whether radiation worked by watching tumor size change on scans weeks or months later. This trial will use the new MRI during and after stereotactic radiation therapy in 150 adults with brain metastases. The goal is to detect early changes in the tumor and to tell apart radiation damage from a tumor that is still growing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A new MRI imaging technique called diffusional variance decomposition (DIVIDE) used during and after stereotactic radiation therapy
What this could lead to
If it works, this could let doctors see early whether radiation is working and adjust treatment sooner, and help tell leftover tumor from radiation damage.
What could go wrong
The technique is new and this trial is early, so it may not reliably predict responses in all patients. MRI-based measures can be affected by many factors, and results may not change practice without larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

150 people

The number who actually took part.

Started

Dec 2020

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients prescribed stereotactic radiation therapy to the brain, where MRI imaging is included in the treatment preparations. 2. Cohesive remaining solid tumor component of ≥10mm. 3. Age ≥18 years. 4. World Health Organisation (WHO) performance status 0-1. Exclusion Criteria: 1. Inability to decide for oneself on participation in the study. 2. Inability to understand the Swedish language. 3. Metastases close to the base of the skull. 4. Contraindications to conducting an MRI examination. 5. Contraindications to obtaining contrast media during MRI examination. 6. Expected survival less than 6 months. 7. Previous radiation treatment to the same site in the brain, i.e. current treatment is a rope radiation. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease brain cancer hypersensitivity reaction disease metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases Radionecrosis Radiotherapy Sensitivity

Contacts and locations

Locations

  • Lund University Hospital

    Lund, 221 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.